Patients with PsA have a higher prevalence of MetS compared with members of the general population and individuals with other inflammatory arthropathies.

Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities. Though metabolic disruption can have significant long-term adverse outcomes for people with ...

A study presented at ACR Convergence 2025 has sparked interest among doctors and patients alike. Drugs originally made for ...

A comprehensive, multi-phase investigation published in Advanced Science suggests that the amino acid tryptophan (Trp) may be a key determinant of therapeutic response to conventional synthetic ...

An observational cohort study uses multi-omics profiling to identify distinct biomarkers that could aid in the earlier ...

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

Inflammatory arthritis resulting from immune checkpoint inhibitor use is immunologically unique and likely driven by T cells ...

Preclinical data highlight MTHFD2 as a promising metabolic target in autoimmune disease, providing strong validation for the ...

A new study led by Swansea University has revealed a new way to potentially treat certain autoimmune diseases by targeting a ...

A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in Rheumatoid Arthritis (RA) patients.

There are many different types of arthritides. The most common of these is osteoarthritis, a degenerative form. Many people are also affected by inflammatory, psoriatic, infectious, or metabolic ...